Discover Global's March 2025 Stocks Estimated Below Fair Value

As global markets navigate a landscape marked by steady interest rates and mixed economic signals, investors are keenly observing the performance of value stocks, which have consistently outperformed growth stocks this year. In such an environment, identifying undervalued stocks becomes crucial as they may offer potential opportunities for those seeking to capitalize on discrepancies between market price and intrinsic value.

Top 10 Undervalued Stocks Based On Cash Flows

Click here to see the full list of 501 stocks from our Undervalued Global Stocks Based On Cash Flows screener.

Let's explore several standout options from the results in the screener.

Turkiye Garanti Bankasi (IBSE:GARAN)

Overview: Turkiye Garanti Bankasi A.S. offers a range of banking products and services in Turkey, with a market cap of TRY517.02 billion.

Operations: The revenue segments for the company include Retail Banking at TRY135.82 billion and Corporate and Commercial Banking at TRY139.33 billion, while Investment Banking recorded a negative contribution of TRY172.86 billion.

Estimated Discount To Fair Value: 18.3%

Turkiye Garanti Bankasi is trading at TRY123.1, 18.3% below its fair value estimate of TRY150.75, suggesting it might be undervalued based on cash flows. Despite a high bad loans ratio of 2.1%, its earnings are projected to grow significantly over the next three years, with revenue expected to rise faster than the Turkish market average. The bank's recent annual dividend increase and strong net income growth further underscore its potential as an undervalued investment opportunity.

• Our growth report here indicates Turkiye Garanti Bankasi may be poised for an improving outlook.
• Unlock comprehensive insights into our analysis of Turkiye Garanti Bankasi stock in this financial health report.

Zhejiang Juhua (SHSE:600160)

Overview: Zhejiang Juhua Co., Ltd. is involved in the research, development, production, and sale of chemical raw materials, chemical products, and food additives in China with a market cap of CN¥65.55 billion.

Operations: The company's revenue primarily comes from its Chemical Industry segment, which generated CN¥22.55 billion.

Estimated Discount To Fair Value: 48.8%

Zhejiang Juhua, trading at CN¥24.4, is priced 48.8% below its estimated fair value of CN¥47.66, highlighting its potential as an undervalued stock based on cash flows. Despite a forecasted low return on equity of 17% in three years, earnings are expected to grow significantly at 42% annually over the same period, outpacing the broader Chinese market's growth rate of 25%. A recent shareholders meeting may influence investor sentiment further.

• The analysis detailed in our Zhejiang Juhua growth report hints at robust future financial performance.
• Delve into the full analysis health report here for a deeper understanding of Zhejiang Juhua.

Hunan Jiudian Pharmaceutical (SZSE:300705)

Overview: Hunan Jiudian Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products both in China and internationally, with a market cap of CN¥8.72 billion.

Operations: The company's revenue is primarily derived from its Medicine Manufacturing segment, which generated CN¥2.95 billion.

Estimated Discount To Fair Value: 43.3%

Hunan Jiudian Pharmaceutical, trading at CN¥18.19, is valued 43.3% below its estimated fair value of CN¥32.07, making it an attractive prospect among undervalued stocks based on cash flows. The company has announced a buyback program worth up to CNY 150 million to enhance shareholder value and support an equity incentive plan. Earnings are projected to grow significantly at 24.88% annually over the next three years, though slightly slower than the broader Chinese market's growth rate of 25%.

• In light of our recent growth report, it seems possible that Hunan Jiudian Pharmaceutical's financial performance will exceed current levels.
• Click here to discover the nuances of Hunan Jiudian Pharmaceutical with our detailed financial health report.

Taking Advantage

• Get an in-depth perspective on all 501 Undervalued Global Stocks Based On Cash Flows by using our screener here.
• Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.
• Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.

Searching for a Fresh Perspective?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com